Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S John Weroha

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|October 17, 2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growthMarc A Becker, Thahir Farzan, Sean C Harrington, et al.
Cancer Research Communications|September 9, 2022
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumorsValentino Clemente, Asumi Hoshino, Mihir Shetty, et al.
Neoplasia (New York, N.Y.)|June 29, 2017
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived XenograftsKristina A Butler, Xiaonan Hou, Marc A Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2012
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumorsMarc A Becker, Xiaonan Hou, Sean C Harrington, et al.
Psycho-Oncology|June 24, 2015
Ureteral obstruction in cancer patients: a qualitative studyAmanika Kumar, Lance Mynderse, Krishna Patel, et al.
Nature Communications|October 13, 2019
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancerArun Kanakkanthara, Catherine J Huntoon, Xiaonan Hou, et al.
Gynecologic Oncology|June 15, 2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomesRiham Suleiman, Shilpa Mokshagundam, Matthew S Block, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Gynecologic Oncology|April 8, 2025
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapyJesus Gonzalez-Bosquet, Maryam Shahi, Siddhartha Yadav, et al.
Neoplasia (New York, N.Y.)|November 30, 2024
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agentsRocco Caggiano, Evgeniia Prokhorova, Lena Duma, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|October 17, 2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growthMarc A Becker, Thahir Farzan, Sean C Harrington, et al.
Cancer Research Communications|September 9, 2022
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumorsValentino Clemente, Asumi Hoshino, Mihir Shetty, et al.
Neoplasia (New York, N.Y.)|June 29, 2017
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived XenograftsKristina A Butler, Xiaonan Hou, Marc A Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2012
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumorsMarc A Becker, Xiaonan Hou, Sean C Harrington, et al.
Psycho-Oncology|June 24, 2015
Ureteral obstruction in cancer patients: a qualitative studyAmanika Kumar, Lance Mynderse, Krishna Patel, et al.
Nature Communications|October 13, 2019
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancerArun Kanakkanthara, Catherine J Huntoon, Xiaonan Hou, et al.
Gynecologic Oncology|June 15, 2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomesRiham Suleiman, Shilpa Mokshagundam, Matthew S Block, et al.
Scientific Reports|April 21, 2019
Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenograftsYuanhang Liu, Pritha Chanana, Jaime I Davila, et al.
Gynecologic Oncology|April 8, 2025
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapyJesus Gonzalez-Bosquet, Maryam Shahi, Siddhartha Yadav, et al.
Neoplasia (New York, N.Y.)|November 30, 2024
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agentsRocco Caggiano, Evgeniia Prokhorova, Lena Duma, et al.
Pageof 9